Halozyme Therapeutics (HALO) Tops Q3 EPS by 6c; Raises Outlook

Halozyme Therapeutics (NASDAQ: HALO) reported Q3 EPS of $0.25, $0.06 better than the analyst estimate of $0.19. Revenue for the quarter came in at $65.3 million versus the consensus estimate of $60.9 million.

GUIDANCE:

Halozyme Therapeutics sees FY2020 EPS of $0.80-$0.85, versus the consensus of $0.69. Halozyme Therapeutics sees FY2020 revenue of $250-260 million, versus the consensus of $235.94 million.

For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.

You May Also Be Interested In

• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• John Wiley & Sons, Inc. (WLYB) Misses Q1 EPS by 2c ; Offers Guidance
• Samsara Inc (IOT) Tops Q2 EPS by 4c, Beats on Revenue; Offers Q3 Guidance